AU2011232745A1 - Curcuminoids and its metabolites for the application in allergic nasal conditions - Google Patents

Abstract

4491-1 29 A pharmaceutical composition(s) for ophthalmic/nasal administration comprising; one or more nano emulsified Curcumin component(s) and/or its metabolites selected from natural or synthetic curcuminoid(s); in combination with a pharmaceutically acceptable 5 excipient(s), effective in increasing the bioavailability of the active compounds is disclosed herein.

Description

4491-1 1 CURCUMINOIDS AND ITS METABOLITES FOR THE APPLICATION IN ALLERGIC NASAL CONDITIONS Technical Field of the invention: 5 The present invention relates to an therapeutic aqueous ophthalmic and nasal composition(s) comprising natural curcuminoids and or its metabolites, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and synthetically derived bis-o demethylcurcumin and/or other demethylated curcuminoids either alone or optionally in 10 combination with suitable surfactants and/or co-solvents as permeation enhancers along with other ophthalmic and nasal excipients, useful for the prevention or treatment of allergic conditions like allergic conjunctivitis, allergic rhinitis and their associated symptoms in humans and animals. 15 Background of the invention: The eye is a complex and sensitive organ of the body, which can experience numerous diseases. The eye poses many barriers to protect any damage to its tissues. This also means that the anterior portion of the eye is more susceptible to diseases. The first and 20 foremost barrier is the conjunctiva, which is the mucous membrane surrounding the eye ball. It is constantly exposed to many harsh conditions/allergens through the environmental factors it encounters. This leads to the allergic reactions in the eye mediated by mast cells through the release of histamine leading to the condition called allergic conjunctivitis or other associated inflammatory conditions like redness and 25 swelling of the eye. These allergic conditions are either seasonal which occurs only during specific time of the year and is termed seasonal allergic conjunctivitis (SAC) or perennial that occurs throughout the year and termed perennial allergic conjunctivitis (PAC). Some allergic conditions extend even to the cornea such as atopic keratoconjunctivitis, vernal conjunctivitis and giant papillary conjunctivitis. 30 These conditions are typically characterized by red, itchy and swollen eyes with watery discharge. This is largely attributed to the degranulation of mast cells due to the cross linking of IgE upon allergen sensitization leading to an outburst of histamine in the conjunctiva. The conjunctiva, being rich in mast cells, experiences an overdose of 35 histamine upon allergen sensitization, resulting in the itching and redness of the eye.

4491-1 2 Current treatment methods involve anti-histamine drops (emedastine difumarate and levocabastine), topical mast cell stabilizers (olopatadine, ketotifen), decongestants and topical anti-inflammatory drugs (NSAID's and corticosteroids). 5 Allergic rhinitis is an inflammation of the nasal passages, usually associated with watery nasal discharge and itching of the nose and eyes. The symptoms occur in the nose and eyes and usually occur after exposure to dust, danders, or certain seasonal pollens. Patients can be severely restricted in their daily activities, resulting in excessive time away from school or work. Millions of dollars are spent each year on physician services 10 and medication for treatment of this chronic illness. Many perennial and seasonal allergens cause allergic rhinitis the former giving rise to perennial allergic rhinitis (PAR) and the latter giving rise to seasonal allergic conjunctivitis (SAR). Dust mites, cockroaches, molds and animal dander, are examples of year-around allergens. 15 Characteristic symptoms include repetitive sneezing; rhinorrhea (runny nose); post-nasal drip; nasal congestion; pruritic (itchy) eyes, ears, nose or throat; and generalized fatigue. Symptoms can also include wheezing, eye tearing, sore throat, and impaired smell. A chronic cough may be secondary to postnasal drip, but should not be mistaken for asthma. Sinus headaches and ear plugging are also common. 20 Anti-histamines and Decongestants for Allergic Conjunctivitis Anti-histamines are available for treating Allergic Conjunctivitis and are available in the market as tablets, capsules and liquids, and may or may not be combined with decongestants. Common anti-histamines include brompheniramine or chlorpheniramine, and clemastine. Non-sedating (less likely to cause drowsiness) long-acting anti 25 histamines include loratidine and fexofenadine. Oral decongestants alone may be helpful, including pseudoephedrine. Nasal sprays For rhinorrhea, a nasal spray of cromolyn sodium (Nasalcrom) or a steroid nasal spray, such as flunisolide (Nasalide), beclomethasone dipropionate (Beconase, Vancenase), 30 triamcinolone acetonide (Nasacort), and fluticasone (Flonase), may work so well that 4491-1 3 additional anti-histamines or decongestants are unnecessary. It is important to remember that improvement may not occur for one to two weeks after starting therapy with steroid nasal sprays. Short courses of oral corticosteroids may usually be indicated when severe nasal symptoms prevent the adequate delivery of topical agents. 5 Health Encyclopedia - Diseases and Conditions But due to their unpleasant side-effects, there has been a tremendous surge in demand for non-steroidal, plant based anti-inflammatory and anti-allergic agents and their potential use in various therapeutic applications. Curcuminoids are one such class of compounds that have proven anti-inflammatory and anti-allergic properties. 10 Curcuminoids are natural, polyphenolic compounds present in turmeric in three different forms a) Curcumin b) Bisdemethoxy curcumin and c) Demethoxy curcumin. Curcumin is the principal curcuminoid and has exceptionally potent antioxidant and anti inflammatory activity, which can prevent cell damage caused by free-radicals (oxidative stress)and inflammation. The current level of interest on curcumin and its 15 analogs/derivatives is known from the below mentioned articles. Process for producing enriched fractions of bis-o-demethylcurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of curcuma longa is disclosed in our earlier PCT Application #WO/2007/043058. According to this publication, bis-o demethyl curcumin shows most potent anticancer, anti-oxidative and anti-inflammatory 20 activity when compared to other curcuminoids and the natural mixture of curcumins. However, the use of natural curcuminoids, such as curcumin, bisdemethoxycurcumin demethoxycurcumin and synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or in combination in ophthalmic formulations is not known in the prior art. Natural curcuminoids, such as curcumin, 25 bisdemethoxycurcumin demethoxycurcumin and synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or in combination being a lipophilic drug have low aqueous solubility, and hence restrict the therapeutic availability of the same. All curcuminoids, both natural and synthetic have lipophilic structures with conjugated 30 double bonds with a keto group thus rendering them to have a dielectric constant which 4491-1 4 will interact with negatively charged membranes making it unable to permeate through the biological membrane. Thus, for these curcuminoids to pass through membranes, it is necessary to encapsulate these molecules with lipophilic molecules. Moreover, it is necessary to make the lattice of molecules as a single entity so that these encapsulated 5 molecules can be transported across membranes. Anti-allergic and anti-inflammatory drugs are classified into analgesics, anti-histamines, anti-microbials, corticosteroids and non steroidal anti-inflammatory drugs (NSAID's). These classes of drugs are used to treat variety of ocular disorders. Prolonged use of corticosteroids, NSAID's, and the other groups of above mentioned classes of drugs 10 results in glaucoma, optic nerve damage, vision problems, cataract, or secondary ocular infections. Summary of the Invention: Accordingly, embodiments of the current invention aim to provide a potential successor 15 in the field of ophthalmology with a novel phytopharmaceutical composition for the treatment of ocular and nasal diseases/disorders. Surprisingly, preliminary experiments conducted have demonstrated the use of surfactants and cosolvents in solubilizing curcuminoids upto 200mg w/v thereby aiding effective solubilization in aqueous medium. The current method involves coating of curcuminoids using surfactants and a 20 cosolvent in order to enhance the curcuminoids aqueous solubility and hence its permeation across the cell membrane. Therefore, embodiments of the current invention provide hitherto unexploited and novel ophthalmic composition(s) comprising natural curcuminoids, such as curcumin, bisdemethoxycurcumin demethoxycurcumin and synthetically derived bis-o-demethyl 25 curcumin and/or other demethylated curcuminoids either alone or in combination, together with surfactants and/or cosolvents as aqueous ophthalmic composition(s) in the form of gel/suspension/ointment for ocular diseases or disorders. In an important aspect, the invention provides an aqueous ophthalmic (topical) eye drop 30 formulation comprising natural curcuminoids and/or its metabolites, such as curcumin, bisdemethoxycurcumin demethoxycurcumin and synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or optionally in 4491-1 5 combination with surfactant, cosolvent along with suitable ophthalmic excipients for inflammatory diseases of eye such as allergic conjunctivitis. In another aspect, the invention provides a pharmaceutical composition(s) for nasal 5 administration comprising; one or more nano emulsified Curcumin component(s) and/or its metabolites selected from natural or synthetic curcuminoid(s); in combination with a pharmaceutically acceptable excipient(s), effective in increasing the bioavailability of the active compounds. 10 In another aspect, the invention provides a nasal spray comprising natural curcuminoids and/or its metabolites, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or in combination with nonionic surfactant, cosolvent along with suitable excipients for inflammatory diseases of the nose such as allergic rhinitis. 15 In another aspect, the invention provides suitable formulation for ophthalmic application described herein as an aqueous ophthalmic drops or ophthalmic gel formulation comprising natural curcuminoids and/or its metabolites, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o 20 demethyl curcumin and/or other demethylated curcuminoids either alone or in combination with pharmaceutically acceptable excipients selected from surfactant(s) and/or cosolvent(s) along with suitable ophthalmic excipients. In another aspect, the invention provides formulation for nasal application enclosed 25 herewith is a spray comprising curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or in combination with pharmaceutically acceptable excipients or suitable nasal excipients. 30 In another aspect, the invention provides compositions comprising one or more Curcuma derived components obtained naturally or by synthesis or semi-synthesis for preparing compositions described in the present invention. In another aspect, the invention provides pharmaceutical composition(s) for nasal 4491-1 6 administration comprising one or more nanoemulsified curcumin components and/or its metabolites selected from natural or synthetic curcuminoid(s) having viscosity in the range of 5-20 centipoise. 5 In another aspect, the method of administration of natural curcuminoids and/or its metabolites, like curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and other demethylated curcuminoids either alone or optionally in combination with a pharmaceutically acceptable excipients or carriers or diluents in a therapeutically effective amount to prevent, retard the 10 development or to reduce the symptoms of several inflammatory diseases such as allergic conditions of the eye/conjunctiva and/or the nasal tract and/or asthma. In another aspect the invention describes use of compositions of the invention for prevention and treatment of ocular and nasal allergic conditions in animals and humans. 15 In yet another aspect the invention describes a method for treating or preventing ocular and nasal allergic conditions in animals and humans wherein said method comprises administration of therapeutically effective amount of the composition according to the present invention. 20 Brief description of figures: Figure I: Figure I depicts Comparison of intracellular transport of nanoemulsified curcumin with plain curcumin and the confocal pictures of Nano emulsified 25 curcuminoids and non-nano emulsified curcuminoids at 5min, 10 min and 25 min. Figure II: Figure II depicts Comparison of intestinal uptake of nanoemulsified curcumin with plain curcumin and the Confocal pictures of nano emulsified curcumin and non nano emulsified curcumin at 1 hr time interval in two different animal groups. 30 Figure III: Figure III depicts Particle Size Study using Malvern particle size analyzer. Figure IV: Figure IV depicts TEM Micrograph: Morphology of nano-emulsion under TEM. 35 4491-1 7 Figure V: Figure V depicts SEM Micrograph: Morphology of nano-emulsion under SEM. Figure VI: Figure VI depicts FRAP assay - total anti-oxidant activity of curcumin. 5 Figure VII: Figure V depicts line diagram showing inhibition of p-hexosaminidase release from PMA-induced U937 human monocytes concomitantly treated with different concentrations curcumin (formulated and non-formulated) as indicated. p hexosaminidase released form the untreated control cells are considered as 100%. 10 Results represented as the mean from quadruplicate culture wells. Figure VIII: Figure VIII depicts line diagram showing inhibition of histamine release from PMA-induced U937 human monocytes concomitantly treated with different concentrations of nonformulated and formulated curcumin. 15 Detailed Description of the Invention: The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully understood and 20 appreciated. As used herein the term 'curcuminoid' or 'curcuminoids' means one or more curcuma derived components comprising natural curcuminoids, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o 25 demethyl curcumin and/or other demethylated curcuminoids either alone or optionally in combination with one or more pharmaceutically acceptable excipients for several inflammatory and allergic diseases in humans and animals in need thereof. As used herein the term 'surfactant' or 'surfactants' means surface active agent(s) which 30 works by lowering the surface tension of water and enabling solubility of lipophilic compounds. The surfactants in nature are amphiphilic, meaning they contain a hydrophobic tail and a hydrophilic head. Therefore, these are soluble in both hydrophobic medium and water. 35 The surfactants are of 2 types a) ionic (anionic and cationic) b) nonionic. The current invention involves the use of anionic, cationic and nonionic surfactants for 4491-1 8 pharmaceutical purposes. The surfactants used in the current invention can be selected from but not limited to polysorbate 80 and 20, poloxamers, octoxynol and any other pharmaceutically acceptable surfactant(s) suitable for preparing the compositions of the present invention. 5 Accordingly, in one embodiment, the current invention provides an aqueous ophthalmic (topical) eye drop or ophthalmic gel formulation comprising one or more Curcuma derived component(s) and their metabolites preferably selected from natural curcuminoids, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or 10 synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or optionally in combination with pharmaceutically acceptable surfactant(s), cosolvent or suitable ophthalmic excipient(s). In another embodiment , the invention provides a nasal spray comprising one or more 15 Curcuma derived component(s) and their metabolites preferably selected from natural curcuminoids, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone or in combination along with suitable excipient(s). 20 In yet another embodiment, the present invention provides an aqueous ophthalmic (topical) eye drop or ophthalmic gel formulation comprising an effective amount of natural/synthetic curcuminoids and an amount of pharmaceutically acceptable surfactant(s) and a cosolvent or suitable ophthalmic excipient(s) effective in increasing the bioavailability of the lipophilic curcuminoids, when administered topically to the eye 25 or an ointment comprising an effective amount of natural/synthetic curcuminoids administered topically to the eye to effectively treat several inflammatory and allergic conditions of the eye and nasal tract. The present invention also provides an ophthalmic eye drop dispenser containing an 30 ophthalmic (topical) composition comprising an effective amount of natural/synthetic curcuminoids, and a pharmaceutically acceptable surfactant(s) and a cosolvent in a therapeutically effective amount to effectively increase the solubility of the naturally active or synthetic component(s) used for preparing the composition(s). The 4491-1 9 composition(s) of this invention are devoid of any side effects and also effective in prolonging the therapeutic effect of the active agent, when administered to the eye. The present invention also provides a nasal spray container comprising an nasal spray 5 composition of an effective amount of one or more natural/synthetic curcuminoids, and in combination with an amount of pharmaceutically acceptable agent(s) such as nonionic surfactant(s) and a cosolvent(s) or suitable nasal excipient(s) effectively to increase the solubility of the naturally active or synthetic component(s) used for preparing the composition(s). 10 The invention provides pharmaceutical drug(s) derived from one or more Curcuma component(s) obtained either naturally or by synthetic or by semi-synthesis. Curcuma or Turmeric is a commonly used spice and coloring agent used in India, and is available from wide sources, having potent anti inflammatory, anti-oxidant and anti-allergic action 15 with no side effect. Curcumin was reported to have anti-allergic properties with inhibitory effect on histamine release from mast cells. The effectiveness of curcumin in allergy and asthma has been further investigated using a murine model of allergy. The results indicate a marked inhibition of allergic response in animals treated with curcumin suggesting a 20 major role for curcumin in reducing the allergic response. The present review focuses on the results of research aimed to understand the immunomodulation induced by curcumin and its associated roles in the amelioration of allergy. These findings needed further evaluation, extrapolation, and confirmation before using curcumin for controlling allergy and asthma in humans. Kurup et al., "Immunomodulatory effects of curcumin in allergy" 25 Mol Nutr Food Res. 2008 Sep; 52(9):1031-9 The desirable preventive or putative therapeutic properties of curcumin have also been considered to be associated with its antioxidant and anti-inflammatory properties. Free radical-mediated peroxidation of membrane lipids and oxidative damage of DNA and proteins are believed to be associated with a variety of chronic pathological 30 complications such as cancer, atherosclerosis, and neurodegenerative diseases. Curcumin is thought to play a vital role against these pathological conditions. The anti inflammatory effect of curcumin is most likely mediated through its ability to inhibit cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible nitric oxide synthase 4491-1 10 (iNOS). COX-2, LOX, and iNOS are important enzymes that mediate inflammatory processes. Improper upregulation of COX-2 and/or iNOS has been associated with the pathophysiology of certain types of human cancer as well as inflammatory disorders. Because inflammation is closely linked to tumor promotion, curcumin with its potent 5 anti-inflammatory property is anticipated to exert chemopreventive effects on carcinogenesis. Hence, the past few decades have witnessed intense research devoted to the antioxidant and anti-inflammatory properties of curcumin. In this review, both antioxidant and anti-inflammatory properties of curcumin, the mode of action of curcumin, and its therapeutic usage against different pathological conditions are clearly 10 described. Menon VP et al., "Antioxidant and anti-inflammatory properties of curcumin "Adv Exp Med Biol. 2007;595:105-25 Anti-asthmatic property of curcumin (diferuloylmethane), a natural product from the rhizomes of Curcuma longa, has been tested in a guinea pig model of airway hyper 15 responsiveness. The guinea pigs were sensitized with ovalbumin (OVA) to develop certain characteristic features of asthma: allergen induced airway constriction and airway hyper reactivity to histamine. Guinea pigs were treated with curcumin during sensitization (to examine its preventive effect) or after developing impaired airways features (to examine its therapeutic effect). Status of airway constriction and airway 20 hyper reactivity were determined by measuring specific airway conductance (SGaw) using a non-invasive technique, constant-volume body plethysmography. Curcumin (20 mg/kg body weight) treatment significantly inhibits OVA-induced airway constriction (p<0.0399) and airway hyper reactivity (p<0.0043). The results demonstrate that curcumin is effective in improving the impaired airways features in the OVA-sensitized 25 guinea pigs. Arjun Ram et al., "Curcumin Attenuates Allergen-Induced Airway Hyperresponsiveness in Sensitized Guinea Pigs", Biological & Pharmaceutical Bulletin Vol. 26 (2003), No. 71021 Thus keeping the above cited references and many other references, in the present invention, it was aimed to the study under trial and to test the benefits of the formulation 30 of curcumin in the treatment or prevention of several inflammatory diseases of eye and nose such as Allergic Conjunctivitis/Allergic Rhinitis which is characterized primarily by itching, redness and edema of the eye due to histamine release.

4491-1 11 Accordingly, the present invention provides ophthalmic compositions/formulation in any suitable form, more specifically as ophthalmic drops or ophthalmic gel, where the formulation may comprise one or more Curcuma derived components such as curcuminoids available from natural or obtained by synthesis or semi-synthesis. 5 In a preferred embodiment, the active agents that may be used include, but are not limited to, constituents of natural curcumin mixture comprising natural curcuminoids, such as curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids either alone 10 or in combination having antioxidant or anti-inflammatory activity. The concentration of total curcuminoids in the compositions of the present invention may vary from 0.01% to 5.0%w/v and more preferably between 0.05% to 2.5%, with an effective concentration of 0.06%.The curcumin components can be derived from one or more curcuma species comprising Curcuma longa, Curcuma aromatica and Curcuma Zedoaria. 15 According to the invention the drug and surfactants can be combined with acceptable carriers to formulate a stable ophthalmic preparation with enhanced bioavailability and stability. These carriers include pharmaceutically acceptable excipients and additives selected from but not limited to water soluble polymers, chelating agents, stabilizing 20 agents, isotonizing agents, buffer substances, preservatives, thickeners, complexing agents, electrolytes and other excipients. The water soluble polymers are selected from but not limited to methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, 25 hydroxypropyl ethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyethylene oxide and chitosan or a derivative thereof. 30 The surfactant(s) can be anionic, cationic or non-ionic selected from but not limited to polysorbate 80 and 20, polyethylene glycol esters, polyethylene glycols, glycerol ethers or mixtures of those compounds. The co-solvents are selected from but not limited to monohydric alcohol or polyhydric 4491-1 12 alcohols such as polyethylene glycol, polypropyleneglycol and the like. The composition further comprises a chelating agent such as disodium salt of EDTA. The composition may comprise suitable water soluble polymers which may be used in 5 the invention but not limited to methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, poly(methyl methacrylate), polycarbophil, gelatin, alginate, poly(acrylic acid), polyethylene oxide and chitosan or a derivative thereof. 10 The stabilizing agent in the present composition comprises of but is not limited to sodium hydrogen sulfite, glycerin, sodium citrate, butyl hydroxyanisole, benzalkonium chloride, edetic acid and pharmaceutically acceptable salts thereof, tocopherol and derivatives thereof, optionally in combination with sodium edetate . 15 The isotonizing agent used in the composition comprises of but is not limited to any specific one like sodium chloride, potassium chloride, D-mannitol, glucose, glycerin, xylitol and propylene. 20 The thickening agent which may be used but not limited to, methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyvinyl alcohol, sodium chondroitin sulfate, sodium hyaluronate and chitosan. Thickening agents are used to maintain the viscosity of the liquid formulations. Accordingly the pharmaceutical composition(s) for nasal administration of the present invention 25 comprises one or more nanoemulsified curcumin components and/or its metabolites selected from natural or synthetic curcuminoid(s) having viscosity in the range of 5-20 centipoise. The preservatives which may be used include but are not limited to, sodium bisulfite, 30 sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol. The buffering agents that may be used include, but are not limited to, sodium carbonate, 35 sodium tetraborate, sodium phosphate, sodium acetate, sodium bicarbonate.

4491-1 13 Electrolytes such as sodium chloride and potassium chloride may also be included in the formulation. 5 The ophthalmic/intra-nasal aqueous pharmaceutical preparation of the present invention may be charged in an appropriate container for better drug delivery. The dosage form of the ophthalmic aqueous pharmaceutical preparation of the present invention is not limited to an eye drop, but may be prepared as ophthalmic gel. For 10 instance, the ophthalmic aqueous pharmaceutical suspension preparation of the present invention can widely be used for the treatment of all the anterior and posterior related conditions or ocular diseases. The dosage form of the intra-nasal aqueous pharmaceutical preparation of the present 15 invention is not limited to nasal spray and can be prepared as nasal drops also. Furthermore, the ophthalmic/nasal aqueous solution preparation of the present invention comprises a non-steroidal drug. Therefore, it may be devoid of any side effect even if it is administered for a prolonged period of time with a low probability of damaging 20 corneal/nasal epithelial cells or the conjunctival cells. Potent curcuminoids such as curcumin, bis-o-demethyl curcumin suppress inflammation by inhibiting edema, fibrin deposition, capillary leakage and phagocytic migration, all key features of the inflammatory response. These curcuminoids prevent the release of 25 prostaglandins, some of which have been identified as mediators of cystoid macular edema. Additionally, curcuminoids including bis-o-demethyl curcumin have been shown to inhibit the expression of vascular endothelial growth factor (VEGF), a cytokine which is a potent promoter of vascular permeability. 30 In order to further validate the hypothesis of the anti-allergic activity of curcuminoids certain ex-vivo and in vivo studies can be performed. Guinea pig ileum study would be an ideal ex-vivo experiment where the allergen sensitized guinea pig ileum is treated with the formulation and assessed for its efficacy. In the same way the formulation can be tested in vivo by sensitizing the animals with histamine and treating with the 35 formulation and assessing for its efficacy.

4491-1 14 The use of curcuminoids to date, by conventional routes of administration, has yielded limited success in treating eye disorders, including macular edema, largely due to the inability to deliver and maintain adequate quantities of the drug to the posterior segment 5 without resultant toxicity. For example, after usual topical administration of ophthalmic drops, only about 1% reaches the anterior segment, and only a fraction of that amount moves into the posterior segment. Although intravitreal injections of drug have been used, the exposure to the drug is very brief as the half-life of the drug within the eye is approximately 3 hours. 10 In our pervious Indian patent application# PCT/IN2009/000651, a process of solubilization of natural or synthetic curcumin and other curcuminoids has been described using surfactants and cosolvents with the help of sonar energy. 15 It was also found that the nanoemulsified curcumin was effectively taken up by the cells when compared to the normal curcumin. The nanoemulsified curcumin increases the pharmacokinetics and pharmacodynamics properties thereby having a better therapeutic effect. This process enhances the uptake of curcumin and thereby having a potent therapeutic effect. The nano emulsification process enhances the anti-allergic activity of 20 curcumin thus increasing the effectiveness of the formulation when compared any other known therapeutic agents. The nanoparticle size of curcumin in the present invention was found to be between 10 20nm in size. However, the nanodroplet size can vary from 5-500 nm, preferably 5-100 25 nm and more preferably 5-30 nm. Transmission electron microscope (TEM) and Scanning electron microscope (SEM) studies were conducted on the nanoemulsion to confirm the shape and size of the nano particles. A typical eye drop/nasal spray formulation(s) of the present invention comprises of one 30 or more Curcumin derived components selected from an aqueous drug suspension of solid natural curcuminoids, such as curcumin, bisdemethoxycurcumin demethoxycurcumin and synthetically derived bis-o-demethyl curcumin and/or other demethylated curcuminoids with antioxidant or anti-inflammatory activity optionally in combination with pharmaceutically acceptable excipient(s) selected from but not limited 4491-1 15 to nonionic surfactant preferably cyclodextrin complexes, water-soluble polymers such as hydroxypropyl methylcellulose, and other cellulose derivatives, chelating agent, metal ions (such as magnesium ions) and/or organic salts such as sodium acetate and sodium citrate, where such additives are used to stabilize the system with enhanced 5 mucoadhesive properties. In yet another preferred embodiment, the invention describes use of compositions of the invention for prevention and treatment of ocular and nasal allergic conditions in animals and humans. 10 Use of the compositions according to the invention is applicable for prevention and treatment of conditions associated with eye such as allergic conjunctivitis, atopic keratoconjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis and conditions thereof. 15 Use of the compositions according to the invention is applicable for treatment and prevention of conditions associated with nose such as allergic rhinitis. The invention further discloses the use of the compositions according to the invention is applicable for treatment and prevention of Asthma. 20 In another embodiment, the method of administration of natural curcuminoids and/or its metabolites, like curcumin, bisdemethoxycurcumin, demethoxycurcumin and/or synthetically derived bis-o-demethyl curcumin and other demethylated curcuminoids either alone or optionally in combination with a pharmaceutically acceptable excipients 25 or carriers or diluents in a therapeutically effective amount to prevent, retard the development or to reduce the symptoms of several inflammatory diseases such as allergic conditions of the eye/conjunctiva and/or the nasal tract. In another embodiment, the invention describes method of reducing or preventing or 30 retarding the development of conditions associated with eye such as allergic conjunctivitis, atopic keratoconjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis comprises administering an effective amount of composition according to the present invention to a subject suffering with said conditions.

4491-1 16 In another embodiment, the invention describes a method of treating and preventing Asthma comprises administering an effective amount of composition according to the invention to a subject suffering with the asthma. 5 In yet another embodiment, the invention describes a method of treating and preventing conditions associated with nose such as allergic rhinitis comprises administering an effective amount of composition according to the invention to a subject suffering with said conditions. 10 The subject mentioned in the above methods is animal or humans. Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following non-limiting 15 examples describing in detail the methods of preparation and use of the invention. It will be apparent to those skilled in the art that any modifications, both to materials and methods, may be practiced without departing from the scope of the invention. EXAMPLES: 20 Example 1: Preparation of Formulation-1: Table-1 S.No Ingredients Concentration 1 Natural/synthetic 20-2500mg curcuminoid 2 Poly Ethylene Glycol 0.7g-1g 4 Tween 80 0.7g-1g 6 Hydroxy Propyl Methyl 0 ig Cellulose 7 Benzalkonium Chloride 20mg 8 Ethylene Diamine Tetra 100mg Acetic Acid (disodium salt) 9 Sodium tetraborate (0.1M) 3.81g 10 Boric acid (IM) 6.8g 11 NaCl 0.795g 12 Sterile water for Injection 100ml 4491-1 17 Example 2: Preparation of Formulation-2: Table-2 S.No Ingredients Concentration 1 Natural/synthetic 20-2500mg Curcuminoid 2 Poly Ethylene Glycol 0.7g-1g 4 Tween 20 0.7g-1g 6 Hydroxy Propyl Methyl 0.1g Cellulose 7 Benzalkonium Chloride 20mg 8 Ethylene Diamine Tetra 100mg Acetic Acid (disodium salt) 9 Sodium tetraborate (0.1M) 3.81g 10 Boric acid (IM) 6.8g 11 NaCl 0.795g 12 Sterile water for Injection 100ml 5 Example 3: Preparation of Formulation-3: Table-3 10 S.No Ingredients Concentration 1 Natural/synthetic 20-2500mg Curcuminoid 2 Poly Ethylene Glycol 0.7g-1g 4 Octoxynol 0.7g-1g 6 Hydroxy Propyl Methyl 0.ig Cellulose 7 Benzalkonium Chloride 20mg Ethylene Diamine Tetra 8 Acetic Acid (disodium 100mg salt) 9 Sodium tetraborate (0.1M) 3.81g 10 Boric acid (1M) 6.8g 11 NaCl 0.795g 12 Sterile water for Injection 100ml 4491-1 18 Example 4: Preparation of Formulation-4: Table-4 5 S.No Ingredients Concentration 1 Natural/synthetic 20-2500mg Curcumin 2 Poly Ethylene Glycol 0.7g-1g 4 Poloxamers 0.7g-1g 6 Hydroxy Propyl Methyl 0.lg Cellulose 7 Benzalkonium Chloride 20mg Ethylene Diamine Tetra 8 Acetic Acid (disodium 100mg salt) 9 Sodium tetraborate 3.81g (0.1M) 10 Boric acid (IM) 6.8g 11 NaCl 0.795g 12 Sterile water for Injection 1OOml Example 5: A typical nasal formulation of 0.06% 10 Table-5 S.No Ingredients Concentration 1 Curcumin 60mg 2 Poly Ethylene Glycol ig 4 Tween 80 ig 6 Hydroxy Propyl Methyl 0.lg Cellulose 7 Benzalkonium Chloride 20mg 8 Ethylene Diamine Tetra 100mg Acetic Acid (disodium salt) 9 Sodium tetraborate (0.1M) 3.81g 10 Boric acid (IM) 6.8g 11 NaCl 0.795g 12 Sterile water for Injection 100ml 4491-1 19 Example 6: Comparison of intracellular transport of nanoemulsified curcumin with plain curcumin Subject: Caco-2 cell incubated with 60tg/ml concentration of nanoemulsified and plain curcumin were used of the study. 5 Experimental method: The study was conducted to evaluate the uptake of nanoemulsified curcumin intracellularly. Cells were grown on the transwell inserts to 100% confluence. The cells were than incubated with nanoemulsified and plain curcumin with a concentration of 60 g/ml for 5min, 10min and 20mins. At later stage the inserts were washed with HBSS buffer and fixed with 3% paraformaldehyde. The 10 insert was than cut and mounted on a slide and covered with a cover slip. These slides were than studied under confocal microscope at 63x. The methodology of the test is detailed in Table-6 and the results are summarized in Figure-I. Table-6 Cells Caco-2 Conc. Of Curcumin 60 g/ml Treatment groups 2(NE-nanoemulsified; NNE- non nanoemulsified Incubation period 5min, 10min and 20mins 15 Example 7: Comparison of the uptake of nanoemulsifed curcumin vs plain curcumin into intestinal cells of mice using the isolated intestinal loop model 20 Confocal microscopy studies were performed on cryosectioned mice intestinal tissue samples to determine the intracellular uptake of curcumin by the intestinal epithelial cells using the isolated intestinal loop model. Briefly the mice were anesthetized with xylazine/ketamine and cut open. Following this the intestines were exposed and the ileum was identified and a loop was tied at the top and bottom of the ileum using 25 surgical sutures without detaching from the mesenchymal system after flushing out the intestinal contents. The drug solutions at a concentration of 300ug/ml for the respective groups were introduced into the lumen using a syringe with a polythene tube attached to the needle and incubated for 60 mins. After 60 mins the tissues were excised and frozen in liquid nitrogen immediately. The tissues were then subjected to cryosectioning and 30 mounted on a slide and covered using a cover slip after which they were studied under 4491-1 20 the confocal microscope at 63x. The results are summarized in Figure-II. No.of groups :- 2 (Nanoemulsified (NE); Plain Curcumin (NNE)) No.of animals/group:- 2 5 Example 8: Particle Size Study using Malvern particle size analyzer The particle size is analyzed by using Malvern particle size analyzer. The particle size (powder, suspensions and emulsions) is measured by diffraction and diffusion of laser beam. For the purpose of laser diffraction measurement, the particles are exposed to a laser beam. The particles scatter light at an angle that is inversely proportional to their 10 size. Photosensitive detectors are used to measure the angular intensity. A map of angle versus scattering intensity gives the particle size value. The droplet size of the nanoemulsions was determined by Malvern particle size analyzer particle analyzer and was found to be 10.55nm. The results of particle size analysis by Malvern particle size analyzer are summarized in Figure III. 15 Table 7. Peaks Size of the particles PDI Peak-1 10.55 0.2387 Example 9: Characterization of Nanoemulsion by TEM The morphology and structure of the nanoemulsion were studied using transmission 20 electron microscopy (TEM). A combination of bright-field imaging at increasing magnification and of diffraction modes was used to reveal the form and size of the nanoemulsion. To perform the TEM observations, the nanoemulsion formulation was diluted with water (1/100). A drop of the diluted nanoemulsion was directly deposited on the holey film grid and observed after drying. The image result of nanoemulsion clearly 25 showed that the nanoparticles are spherical in shape and size varied from 10-20nm. The TEM image of the nanoemulsion is shown in figure-IV Example 10: Characterization of Nanoemulsion by SEM SEM studies on the nanoemulsion showed that the particles were spherical in shape and 30 size was in nano meter range (figure -V). The particle size was in the range of 10-20nm.

4491-1 21 Example 11: FRAP assay (total antioxidant activity) for Curcumin: The FRAP assay (TPTZ assay) developed by Benzie and Strain [R] was employed to measure the total antioxidant activity of the Curcumin in comparison to Vitamin C and Gallic acid. The assay mixture contained 2.5 mL 300 mM acetate buffer pH 3.6, 0.25 5 mL 10 mM TPTZ solution in 40 mM HCl, 0.25 mL 20 mM FeCl3 and Curcumin in 0.1 mL water or methanol. 30 minutes after incubation the absorbance was measured at 593 nm using Cary-50, UV-Vis spectrophotometer. Standard graphs were constructed using known concentrations of ferrous salt in water / methanol to replace FeCl3. All tests were run in triplicate and mean values were used to calculate ECI values. ECI is defined as 10 concentration of antioxidant having a ferric reducing ability equivalent to that of 1 mM ferrous salt. Result: The IC50 value in mcg/ml was found to be 6.92 for natural curcumin (Figure VI). 15 Example 12: Anti-allergic Study The pre-clinical model used for the ocular allergy study is based on sensitizing the animals against the allergen egg albumin followed by challenging the conjunctiva by egg albumin to produce ocular allergy. Twenty four animals (SD rats) in the age group of 10 20 to 14 weeks were used for this study, comprising of four groups with 6 animals in each group. Group 1 serves as a naive control (neither induced nor treated), group 2 serves as the egg albumin induced group, group 3 serves as the curcumin ophthalmic drops treated group and group 4 animals are treated only with the vehicle used for ophthalmic solution preparation. All the animals in the group 2, group 3 and group 4 are sensitized with 1ml 25 intraperitoneal injection of suspension containing 100ptg egg albumin and 20 mg alum for 14 days. On 15 th day 10 pl of IM DL-Dithiothreitol (DTT) in Phosphate buffered saline (pH - 7.4) was applied to the conjunctiva and 10 min later the conjunctiva was topically challenged with lOpl egg albumin (100mg/ml) prepared in phosphate-buffered saline to produce ocular allergy. Drug efficacy was tested by installing the Curcumin 30 based ophthalmic solution to the eye of rats in group 3 by gently opening the eyelids of the rats 10 minutes before the DTT and allergen challenge. The animals in group 4 were treated with the similar manner with the vehicle. The hyperemia and edema of the conjunctiva was then measured on a 0 - 4 point conjunctival scoring system at 0 min, 20 min, 45 min, 90 min and at the end of 4 th hour and the effectiveness of the drug was 35 shown by the reduction in conjunctival redness and conjunctival edema when compared 4491-1 22 to baseline. Example 13: Inhibition of P-hexosaminidase by nanoemulsified curcumin In a present study, the comparative efficacies on inhibition of P-Hexosaminidase release 5 by unformulated and formulated compositions of curcumin (nanoemulsified) in Phorbol ester (PMA) induced model of U937 human monocyte was assessed. Briefly, equal number (50,000 cells) of U937 human monocytes was plated in each well of 96-well cell culture plate. The cells were treated with different concentrations of unformulated and formulated compositions of curcumin in presence or absence of either 20 nM PMA. The 10 cell culture supernatants collected from either untreated control or treated cultures were clarified at 10,000g for 5 min at 4 0 C; and assessed for released -hexosaminidase (6). Measurement of Hexosaminidase Twenty microliter aliquots of cell culture supernatant was incubated with 20 pl of 1 mM p-nitrophenyl-N-acetyl--D-glucosaminide in 0.1 M 15 sodium citrate buffer (pH 4.5) at 37 C for 1 h. At the end of the incubation, 250 1tl of a 0.1 M Na2CO3, 0.1 M NaHCO 3 buffer (pH 10.0) was added. Absorbance was measured at 405 nm. Each treatment was done in quadruplicate wells. The mean OD obtained from the control cultures was considered as 100% release of hexosaminidase. The comparative efficacies in inhibiting P-hexosaminidase release by curcumin and its 20 respective nanoemulsified formulations in PMA induced human monocytes are depicted in Figures VII. Example 15: Inhibition of Histamine release by nanoemulsified Curcumin An equal number (50,000 cells) of U937 human monocytes were plated in each well of 25 96-well cell culture plate. The cells were treated with different concentrations of non formulated and formulated curcumin (nanoemulsified) compositions in presence or absence of 20 nM PMA for 1h. The cell culture supernatants collected from either untreated control or treated cultures were clarified at 10,000g for 5 min at 4 0 C; and assessed for released histamine by a commercially available EIA kit (SPI-Bio, France). 30 The concentrations of the released histamine in the culture supernatants from PMA induced human monocytes treated with curcumin and its nanoemulsified formulations are depicted in Figures VIII. Method for preparation of the formulation: 4491-1 23 Preparation of borate buffer: 1) 3.81g of sodium tetraborate was weighed into a beaker and dissolved in 100ml of 5 water. 2) 6.8g of boric acid was weighed into a beaker and dissolved in 100ml of water. 3) pH of sodium tetraborate solution was checked and found to be in the range of 9. This was adjusted to a pH of 7.2 by the addition of boric acid. 4) The buffer thus prepared was used to adjust pH of the formulation. 10 Solubilization of curcumin: 1) 60mg curcumin was weighed into a 10ml beaker 2) To this 1 g (765ul) Tween80 and Ig PEG was added and stirred well using a 15 glass rod. 3) Following this the tube was sonicated for 30min or till the curcumin is completely solubulized. A deep red colour solution was formed. 20 Preparation of ophthalmic formulation: 1) 100 ml water was placed into a beaker on a magnetic stirrer. 2) HPMC was added and stirred till all the HPMC dissolved. 3) The curcumin + tween80 solution was added drop by drop into this stirred for 15 mins. 25 4) To this BAC, EDTA and NaCl was added and stirred till all the contents dissolve completely and a yellow colour clear solution was obtained. 5) pH of the solution was checked and found to be in the range of 5.3-5.4. Thus it was adjusted with the borate buffer to a pH of 6.5. 30 Unless the context clearly requires otherwise, throughout the description and any claims the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

4491-1 24 The features of the invention described or mentioned in this document may be combined in any combination of features where features are not mutually exclusive. It will be evident to those skilled in the art that the invention is not limited to the details 5 of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning 10 and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (10)

1. 4491-1 25 The claims defining the invention are as follows: 1. A pharmaceutical composition(s) for nasal administration comprising; one or more nano emulsified Curcumin component(s) and/or its metabolites selected from natural or synthetic curcuminoid(s); in combination with a 5 pharmaceutically acceptable excipient(s), effective in increasing the bioavailability of the active compounds.
2. 2. The composition according to claim 1, wherein the curcumin component(s) and/or its metabolites comprise one or more selected from curcumin, bisdemethoxycurcumin, demethoxycurcumin, bis-o-demethyl curcumin and/or 10 other demethylated curcuminoids.
3. 3. The composition according to claim 1 or claim 2, wherein the curcumin component(s) and/or its metabolites are selected from natural/synthetic/semi synthetic origin.
4. 4. The composition according to any one of the preceding claims, wherein the 15 droplet size of nano-emulsion of Curcumin component(s) varies in the range of from 5-500nm.
5. 5. The composition according to any one of the preceding claims, wherein the droplet size of nano-emulsion of Curcumin component(s) varies preferably in the range of 10-20nm. 20
6. 6. The composition according to any one of the preceding claims, wherein the amount of curcuminoids vary from 0.01% to 5% w/v.
7. 7. The composition according to any one of the preceding claims, wherein the amount of curcuminoids preferably vary from 0.050% to 0.150%w/v.
8. 8. The composition according to any one of the preceding claims, wherein the 25 composition is formulated as an aqueous form.
9. 9. The composition according to any one of the preceding claims, wherein curcumin component(s) and/or its metabolites are derived from one or more species selected from Curcuma longa, Curcuma aromatica and Curcuma zedoaria. 30 10. The composition as claimed in any one of the preceding claims, wherein the composition comprises one or more pharmaceutically acceptable excipient(s) selected from surfactant(s) and co-solvent(s). 11. The composition according to claim 10, wherein the surfactant(s) (anionic, cationic and/or non-ionic) is selected from but not limited to polysorbate 80 and 4491-1 26 20, polyethylene glycol esters, polyethylene glycols, glycerol ethers or mixtures of those compounds. 12. The composition according to claim 10 or claim 11, wherein the co-solvent(s) are selected from monohydric alcohol or polyhydric alcohols such as polyethylene 5 glycol, and polypropeleneglycol. 13. The composition according to any one of the preceding claims, wherein the composition comprises one or more pharmaceutically acceptable nasal excipients selected from water soluble polymers, chelating agent, stabilizing agent, isotonizing agents, buffer substances, preservatives, thickeners and electrolytes.
10. 10 14. The composition according to claim 13, wherein the water soluble polymers is selected from but not limited to methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene glycol, poly(methyl methacrylate), 15 polycarbophil, gelatin, alginate, poly(acrylic acid), polyethylene oxide and chitosan or a derivative thereof. 15. The composition according to claim 13 or claim 14, wherein the chelating agent is disodium salt of EDTA. 16. The composition according to any one of claims 13 to 15, wherein the stabilizing 20 agent is selected from sodium hydrogen sulfite, glycerin, sodium citrate, butyl hydroxyanisole, benzalkonium chloride, edetic acid and pharmaceutically acceptable salts thereof, tocopherol and derivatives thereof, with sodium edetate. 17. The composition according to any one of claims 13 to 16, wherein the isotonizing agent is selected from, sodium chloride, potassium chloride, D 25 mannitol, glucose, glycerin, xylitol and propylene. 18. The composition according to any one of claims 13 to 17, wherein the thickening agent is selected from methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, polyvinyl alcohol, sodium chondroitin sulfate, sodium hyaluronate and chitosan. 30 19. The composition according to any one of claims 13 to 18, wherein the preservatives is selected from sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol. 4491-1 27 20. The composition according to any one of claims 13 to 19,wherein the buffering agent is selected from but not limited to, sodium carbonate, sodium tetraborate, sodium phosphate, sodium acetate, sodium bicarbonate. 21. The composition according to any one of claims 13 to 20, wherein the electrolyte 5 is selected from sodium chloride and potassium chloride. 22. The composition according to any one of the preceding claims, wherein the composition comprising curcumin and/or its metabolites has anti-allergic, anti oxidant and anti-inflammatory activity. 23. The pharmaceutical composition(s) for nasal administration comprising one or 10 more nanoemulsified curcumin components and/or its metabolites selected from natural or synthetic curcuminoid(s) according to any one of the preceding claims having viscosity in the range of 5-20 centipoise. 24. Use of the composition according to any one of the preceding claims, wherein the nasal formulation(s) are applicable for prevention and treatment of nasal 15 allergic conditions in animals and humans. 25. Use of the composition according to any one of claims I to 23, wherein, aqueous preparations are nasal spray/nasal drops comprising one or more natural curcuminoids and/or its metabolites. 26. Use of the composition according to any one of claims 1 to 23, wherein the 20 formulation is applicable for treatment and prevention of conditions associated with nose, such as allergic rhinitis. 27. Use of the composition according to any one of claims 1 to 23, wherein the formulation is applicable for treatment and prevention of Asthma. 28. A method of treating and preventing Asthma comprising administering an 25 effective amount of the composition according to any one of claims 1 to 23 to a subject suffering with the asthma. 29. A method of treating and preventing conditions associated with the nose such as allergic rhinitis, comprising administering an effective amount of the composition according to any one of claims 1 to 23 to a subject suffering with 30 said conditions. 30. A method according to claim 28 or 29, wherein said subject is animal or human. 31. A pharmaceutical composition for nasal administration substantially as herein described with reference to the examples. 32. Use of a pharmaceutical composition for prevention and treatment of nasal 4491-1 28 allergic conditions in animals and humans.substantially as herein described with reference to the examples. 33. A method of treating and preventing asthma or conditions associated with the nose substantially as herein described with reference to the examples. 5 Dated 5 October 2011 Laila Pharmaceuticals Pvt. Ltd. 10 By its Patent Attorneys Acumen Intellectual Property